Xp11.2 Translocation Renal Cell Carcinomas Have a Poorer Prognosis Than Non-Xp11.2 Translocation Carcinomas in Children and Young Adults: A Meta-analysis

Abstract

Objectives. Renal cell carcinomas (RCCs) in children and adolescents are much rarer than in adults. In this age group, Xp11.2 translocation RCCs were the most common subtype of pediatric RCCs. Information regarding the clinical behavior of pediatric RCCs remains controversial because of their relatively rare incidence. The authors aimed to perform a systematic review and meta-analysis to better define the biological features of pediatric RCCs. Methods. Eligible studies were identified through multiple search strategies. Studies were assessed for quality using the Jadad Quality Scale. Data were collected comparing overall survival (OS), disease-free survival (DFS), and stage in patients with TFE3 + pediatric RCCs and TFE3 − RCCs. Results. A total of 4 studies were included for meta-analysis, and pooled odds ratios (ORs) with 95% confidence interval (CI) were calculated. The meta-analysis outcomes showed that TFE3 + pediatric RCCs were significantly associated with poorer outcomes (OS and DFS) and a higher stage (III/IV) than TFE3 − RCCs (pooled ORs for each group: 4.59 [95% CI = 1.46-14.42] for OS; 5.79 [95% CI = 1.85-18.16] for DFS; and 5.89 [95% CI = 2.23-15.52] for stage). This result was also confirmed by OS and DFS curves (P = .005 and P = .001). Conclusions. Xp11.2 translocation carcinomas appear to have a poorer prognosis than non-Xp11.2 translocation carcinomas in children and young adults.

Keywords

pediatric renal cell carcinoma TFE3 Xp11.2 translocation carcinomas prognosis

Get full access to this article

View all access options for this article.

References

Cook A. , Lorenzo AJ , Salle JL , et al. Pediatric renal cell carcinoma: single institution 25-year case series and initial experience with partial nephrectomy. J Urol. 2006;175:1456-1460; discussion 1460.

Argani P. The evolving story of renal translocation carcinomas. Am J Clin Pathol. 2006;126:332-334.

Winarti NW , Argani P. , De Marzo AM , et al. Pediatric renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion. Int J Surg Pathol. 2008;16:66-72.

Jing H. , Tai Y. , Xu D. , et al. Renal cell carcinoma associated with Xp11.2 translocations, report of a case [published online ahead of print October 23, 2009]. Urology. doi:10.1016/ j.urology.2009.07.1276.

Lopez-Beltran A. , Scarpelli M. , Montironi R. , et al. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49:798-805.

Martignoni G. , Pea M. , Gobbo S. , et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas . Mod Pathol. 2009; 22:1016-1022.

Argani P. , Ladanyi M. Recent advances in pediatric renal neoplasia. Adv Anat Pathol . 2003;10:243-260.

Argani P. , Lal P. , Hutchinson B. , et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27:750-761.

Dickson BC , Brooks JS , Pasha TL , et al. TFE3 expression in tumors of the microphthalmia-associated transcription factor (MiTF) family [published online ahead of print February 16, 2010]. Int J Surg Pathol. doi:1066896909352861v1.

10.

Geller JI , Dome JS Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. 2004;101:1575-1583.

11.

Geller JI , Argani P. , Adeniran A. , et al. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008;112:1607-1616.

12.

Bovio IM , Allan R. , Oliai B. , et al. Xp11.2 translocation renal carcinoma with placental metastasis: a case report [published online ahead of print January 22, 2009]. Int J Surg Pathol. doi:1066896908331231v1.

13.

Koie T. , Yoneyama T. , Hashimoto Y. , et al. An aggressive course of Xp11 translocation renal cell carcinoma in a 28-year-old man. Int J Urol. 2009;16:333-335.

14.

Jadad AR , Moore RA , Carroll D. , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.

15.

Kjaergard LL , Villumsen J. , Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001;135: 982-989.

16.

Higgins JP , Thompson SG Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.

17.

Higgins JP , Thompson SG , Deeks JJ , et al. Measuring inconsistency in meta-analyses. BMJ . 2003;327:557-560.

18.

Ramphal R. , Pappo A. , Zielenska M. , et al. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family. Am J Clin Pathol. 2006;126:349-364.

19.

Wu A. , Kunju LP , Cheng L. , et al. Renal cell carcinoma in children and young adults: analysis of clinicopathological, immunohistochemical and molecular characteristics with an emphasis on the spectrum of Xp11.2 translocation-associated and unusual clear cell subtypes. Histopathology. 2008;53:533-544.

20.

Rao Q. , Chen YJ , Wang DJ , et al. Renal cell carcinoma in children and young adults: clinicopathological, immunohistochemical, and VHL gene analysis of 46 cases with follow-up [published online ahead of print December 24, 2009]. Int J Surg Pathol . doi:1066896909354337v1.

21.

Moher D. , Pham B. , Jones A. , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet . 1998;352:609-613.

22.

Srigley JR , Delahunt B. Uncommon and recently described renal carcinomas. Mod Pathol . 2009;22(suppl 2):S2-S23.

23.

Rais-Bahrami S. , Drabick JJ , De Marzo AM , et al. Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapy-associated secondary malignancy. Urology. 2007;70:178. e3-e6.